These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 2114942

  • 1. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
    Schiller JH, Storer B, Witt PL, Nelson B, Brown RR, Horisberger M, Grossberg S, Borden EC.
    Cancer Res; 1990 Aug 01; 50(15):4588-94. PubMed ID: 2114942
    [Abstract] [Full Text] [Related]

  • 2. A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.
    Schiller JH, Storer B, Paulnock DM, Brown RR, Datta SP, Witt PL, Borden EC.
    J Clin Invest; 1990 Oct 01; 86(4):1211-21. PubMed ID: 2120284
    [Abstract] [Full Text] [Related]

  • 3. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
    Goldstein D, Sielaff KM, Storer BE, Brown RR, Datta SP, Witt PL, Teitelbaum AP, Smalley RV, Borden EC.
    J Natl Cancer Inst; 1989 Jul 19; 81(14):1061-8. PubMed ID: 2472488
    [Abstract] [Full Text] [Related]

  • 4. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
    Ravandi F, Estrov Z, Kurzrock R, Breitmeyer JB, Maschek BJ, Talpaz M.
    Clin Cancer Res; 1999 Dec 19; 5(12):3990-8. PubMed ID: 10632330
    [Abstract] [Full Text] [Related]

  • 5. Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor.
    Schiller JH, Witt PL, Storer B, Alberti D, Tombes MB, Arzoomanian R, Brown RR, Proctor RA, Voss SD, Spriggs DR.
    Cancer; 1992 Jan 15; 69(2):562-71. PubMed ID: 1728387
    [Abstract] [Full Text] [Related]

  • 6. Phase I trial of combinations of recombinant interferons beta(ser) and gamma in patients with advanced malignancy.
    Schiller JH, Storer B, Willson JK, Borden EC.
    Cancer Treat Rep; 1987 Oct 15; 71(10):945-52. PubMed ID: 3115570
    [Abstract] [Full Text] [Related]

  • 7. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients.
    Witt PL, Ritch PS, Reding D, McAuliffe TL, Westrick L, Grossberg SE, Borden EC.
    Cancer Res; 1993 Nov 01; 53(21):5176-80. PubMed ID: 8221654
    [Abstract] [Full Text] [Related]

  • 8. Activation of 2',5'-oligoadenylate synthetase and B-2 microglobulin in cancer patients treated with partially pure gamma interferon: dependence of biological effect on administration route.
    Rosenblum MG, Riso A, Gutterman JU.
    Cancer Chemother Pharmacol; 1986 Nov 01; 16(3):273-6. PubMed ID: 3084109
    [Abstract] [Full Text] [Related]

  • 9. Prolonged interferon-gamma application by subcutaneous infusion in cancer patients: differential response of serum CD14, neopterin, and monocyte HLA class I and II antigens.
    Landmann R, Ludwig C, Wesp M, Fisscher A, Obrist R, Knüsli C, Denz H, Obrecht JP.
    J Interferon Res; 1992 Apr 01; 12(2):103-11. PubMed ID: 1374454
    [Abstract] [Full Text] [Related]

  • 10. Effects of combinations of interferon-beta ser and interferon-gamma on interferon-inducible proteins and on the cell cycle.
    Schiller JH, Horisberger MA, Bittner G, Carlin JM, Storer B, Byrne GI, Willson JK, Borden EC.
    J Biol Response Mod; 1990 Aug 01; 9(4):368-77. PubMed ID: 2395002
    [Abstract] [Full Text] [Related]

  • 11. Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly.
    Schiller JH, Storer BE, Witt PL, Alberti D, Tombes MB, Arzoomanian R, Proctor RA, McCarthy D, Brown RR, Voss SD.
    Cancer Res; 1991 Mar 15; 51(6):1651-8. PubMed ID: 1998956
    [Abstract] [Full Text] [Related]

  • 12. Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma.
    Fierlbeck G, Ulmer A, Schreiner T, Stroebel W, Schiebel U, Brzoska J.
    J Interferon Cytokine Res; 1996 Oct 15; 16(10):777-81. PubMed ID: 8910762
    [Abstract] [Full Text] [Related]

  • 13. Induced proteins in human peripheral mononuclear cells over a range of clinically tolerable doses of interferon-gamma.
    Paulnock DM, Havlin KA, Storer BM, Spear GT, Sielaff KM, Borden EC.
    J Interferon Res; 1989 Aug 15; 9(4):457-73. PubMed ID: 2502586
    [Abstract] [Full Text] [Related]

  • 14. Minimal dose of aerosolized interferon-alpha in human subjects: biological consequences and side-effects.
    Giosuè S, Casarini M, Ameglio F, Alemanno L, Saltini C, Bisetti A.
    Eur Respir J; 1996 Jan 15; 9(1):42-6. PubMed ID: 8834332
    [Abstract] [Full Text] [Related]

  • 15. Phase I trial of human lymphoblastoid interferon with whole body hyperthermia in advanced cancer.
    Robins HI, Sielaff KM, Storer B, Hawkins MJ, Borden EC.
    Cancer Res; 1989 Mar 15; 49(6):1609-15. PubMed ID: 2647291
    [Abstract] [Full Text] [Related]

  • 16. In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma.
    Kirkwood JM, Ernstoff MS, Trautman T, Hebert G, Nishida Y, Davis CA, Balzer J, Reich S, Schindler J, Rudnick SA.
    J Clin Oncol; 1990 Jun 15; 8(6):1070-82. PubMed ID: 2112184
    [Abstract] [Full Text] [Related]

  • 17. Phase I trial of recombinant interferon gamma by 1-hour i.v. infusion.
    Vadhan-Raj S, Nathan CF, Sherwin SA, Oettgen HF, Krown SE.
    Cancer Treat Rep; 1986 May 15; 70(5):609-14. PubMed ID: 3085930
    [Abstract] [Full Text] [Related]

  • 18. Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.
    Weiner LM, Li W, Holmes M, Catalano RB, Dovnarsky M, Padavic K, Alpaugh RK.
    Cancer Res; 1994 Aug 01; 54(15):4084-90. PubMed ID: 8033141
    [Abstract] [Full Text] [Related]

  • 19. Phase I evaluation of a synthetic mutant of beta-interferon.
    Hawkins M, Horning S, Konrad M, Anderson S, Sielaff K, Rosno S, Schiesel J, Davis T, DeMets D, Merigan T.
    Cancer Res; 1985 Nov 01; 45(11 Pt 2):5914-20. PubMed ID: 4053062
    [Abstract] [Full Text] [Related]

  • 20. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
    Greenblatt MS, Mangalik A, Ferguson J, Elias L.
    Clin Cancer Res; 1995 Jun 01; 1(6):615-20. PubMed ID: 9816023
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.